Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 0707 • ACR Convergence 2023
Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
Chiara Marvisi¹, Giulia Besutti², Pamela Mancuso³, Roberto Farì⁴, Filippo Monelli⁴, Matteo Revelli⁴, Rexhep Durmo⁵, Elena Galli⁶, Francesco Muratore⁷, Lucia Spaggiari², Marta Ottone³, Stefano Luminari⁸, Pierpaolo Pattacini⁴, Paolo Giorgi Rossi³ and Carlo Salvarani⁹, ¹IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ³Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁴Radiology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁵Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁸Ematology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Arterial wall calcifications are a hallmark of atherosclerosis and represent an important cardiovascular risk factor. Accelerated atherosclerosis and vascular calcifications have been reported in…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: 1239 • ACR Convergence 2023
Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort
Ana Luiza Altaffer¹, Kristina Ciaglia², Elizabeth Sloan³ and Marietta De Guzman⁴, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴Baylor College of Medicine, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
Abstract Number: 1567 • ACR Convergence 2023
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
Tanaz Kermani¹, SEMA KAYMAZ-TAHRA², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine G Sreih¹², Kenneth Warrington¹³, fatma Alibaz-Öner¹⁴, Haner Direskeneli¹⁵ and Peter Merkel⁷, ¹Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Bristol Myers Squibb, Princeton Pike, NJ, ¹³Mayo Clinic, Rochester, MN, ¹⁴Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: Damage is the irreversible consequence of disease or its treatment. This study aimed to evaluate the accrual of damage in Takayasu's arteritis (TAK) using…
Abstract Number: 1568 • ACR Convergence 2023
Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci Yildirim⁷, Zeliha Ademoglu⁸, Elif Durak Ediboglu⁹, Burcu Ceren Ekti Uludogan¹⁰, Can Ilgin¹¹, Sule Yasar Bilge¹², Timucin Kasifoğlu¹², Servet Akar⁹, Hakan Emmungil⁸, Fatos Onen¹³, Ahmet Omma⁶, Nilufer Alpay Kanitez¹⁴, Ayten Yazici⁴, Ayse Cefle¹⁵, Murat Inanç¹⁶, Kenan Aksu¹⁷, Gökhan Keser¹⁷, Haner Direskeneli¹⁸ and fatma Alibaz-Öner¹⁹, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University, Izmir, Turkey, ⁸Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Katip Celebi University Faculty of Medicine, Izmir, Turkey, ¹⁰Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹¹Marmara University Faculty of Medicine, Istanbul, Turkey, ¹²Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, ¹³Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Koc University Faculty of Medicine, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, ¹⁶Istanbul University, Istanbul, Turkey, ¹⁷Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, ¹⁸Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
Abstract Number: 1569 • ACR Convergence 2023
Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study
Jing Li¹, Yang Zhao², Yang Yu³, Xianan Jian⁴, Yanhong Wang⁵, yunjiao yang⁶, Xinping Tian⁷, Mengtao Li⁷ and Xiaofeng Zeng⁷, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China, ³The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China, ⁴Puyang Oilfield General Hospital, Puyang, China, ⁵Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: To compare the efficacy and safety of tofacitinib and tocilizumab in patients with Takayasu arteritis (TAK) in real world situation. Methods: A post-hoc analysis…
Abstract Number: 1570 • ACR Convergence 2023
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
Emma Rinaldi¹, Corrado Campochiaro², Roberto Padoan³, Chengappa Kavadichanda⁴, Augustine Jose⁴, Kritika Singh⁵, Luca Iorio³, Naomi Viapiana⁶, Upendra Rathore⁵, Elena Marina Baldissera⁶, Vikas Agarwal⁵, Lorenzo Dagna⁷, Durga P Misra⁵ and Alessandro Tomelleri⁸, ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶IRCCS San Raffaele Hospital, Milan, Italy, ⁷Ospedale San Raffaele, Milano, Italy, ⁸Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy
Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Ana Luiza Altaffer¹, Alvaro Orjuela² and Marietta De Guzman², ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Gleice Clemente¹, Maria Teresa Terreri², Bruno Gualano³, Clovis Silva⁴ and Alexandre Wagner De Souza¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de São Paulo, São Paulo, ⁴Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Robert Maughan¹, Andrew Porter¹, Chanaka Dahanayake², Claudia Ianonne¹, Ritu Alapat¹, Charis Pericleous¹, Taryn Youngstein³ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Imperial NHS Trust, London, United Kingdom
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
Abstract Number: 0179 • ACR Convergence 2022
Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies
Lauren Pachman¹, Gabrielle Morgan², Wilfredo Marin³, Sabah Kadri³, Kai Lee Yap³ and Amer Khojah⁴, ¹Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Umm Al-Qura University, Makkah, Saudi Arabia
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease characterized by proximal weakness and skin rash. Although the exact mechanism of JDM is not…
Abstract Number: 0465 • ACR Convergence 2022
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
Diana Prieto-Peña¹, Javier Loricera², Santos Castañeda³, Clara Moriano⁴, Pilar Bernabeu⁵, Paloma Vela-Casampere⁶, F. Javier Narváez⁷, Vicente Aldasoro⁸, Olga Maíz⁹, Jesús Carlos Fernández-López¹⁰, Mercedes Freire¹⁰, Rafael Melero¹¹, Juan Ignacio Villa¹², Beatriz Gonzalez-Alvarez¹³, Roser Solans-Laqué¹⁴, José Luis Callejas¹⁵, Carlos Fernandez-Diaz¹⁶, Salvador Garcia-Morillo¹⁷, Mauricio Minguez¹⁸, Cristina Fernández-Carballido¹⁹, Esteban Rubio²⁰, Eugenio De Miguel²¹, Julio Sánchez-Martín²², Esther Fernandez²³, Sheila Melchor²⁴, Eva Salgado-Pérez²⁵, Beatriz Bravo²⁶, Susana Romero Yuste²⁷, Eva Galíndez-Agirregoikoa²⁸, francisca Sivera²⁹, Ivan Ferraz Amaro³⁰, Cristina Hidalgo³¹, Carlos Romero Gomez³², Carles Galisteo³³, Patricia Moya Alvarado³⁴, Noelia Alvarez-Rivas³⁵, Javier Mendizabal³⁶, Juan Carlos Nieto González³⁷, Juan Ramón de Dios³⁸, Jose Luis Andreu³⁹, Nagore Fernandez-Llanio⁴⁰, Eztizen Labrador⁴¹, Enrique Raya Álvarez⁴², Arantxa Conesa⁴³, Francisco Ortiz-Sanjuan⁴⁴, Sara Manrique Arija³², Iñigo Rua-Figueroa⁴⁵, A. García-valle⁴⁶, Miguel Ángel González-Gay⁴⁷ and Ricardo Blanco², ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Hospital General de Alicante, Alicante, Spain, ⁶Hospital General Universitario Alicante, Alicante, Spain, ⁷Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario de Navarra, Pamplona, Spain, ⁹Hospital Univesitario de Donostia, Donostia, Spain, ¹⁰Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹²Hospital Sierrallana, Torrelavega, Spain, ¹³Hospital Nuestra Señora de la Candelaria, Tenerife, Spain, ¹⁴Hospital Vall d’Hebron, Barcelona, Spain, ¹⁵Hospital San Cecilio, Granada, Spain, ¹⁶H, Murcia, Spain, ¹⁷Hospital Virgen del Rocío, Sevilla, Spain, ¹⁸San Juan de Alicante, Alicante, Spain, ¹⁹Agencia Valenciana de Salud, Alicante, Spain, ²⁰HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, Spain, ²¹Hospital Universitario La Paz, Madrid, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ²⁶Hospital Virgen de las Nieves, Madrid, Spain, ²⁷Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Elda, Alicante, Spain, ³⁰Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Regional Universitario Málaga, Málaga, Spain, ³³Hospital Parc Tauli,, Sabadel, Spain, ³⁴Hospital Parc Tauli, Barcelona, Spain, ³⁵Hospital San Agustin, Aviles, Spain, ³⁶Complejo Hospitalario de Navarra,, Pamplona, Spain, ³⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁸Hospital de Araba, Araba, Spain, ³⁹Hospital Puerta de Hierro, Madrid, Spain, ⁴⁰Hospital Arnau de Vilanova,, València, Spain, ⁴¹Hospital San Pedro, Logroño, Spain, ⁴²Hospital Universitario San Cecilio, Granada, Spain, ⁴³Hospital Universitario de Castellón, València, Spain, ⁴⁴Hospital Universitario de La Fe, València, Spain, ⁴⁵Hospital Doctor Negrín, Gran Canaria, Spain, ⁴⁶Completo Asistencial Palencia, Palencia, Spain, ⁴⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). However, LVV-GCA and TAK…
Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Despina Michailidou¹, Bhargavi Duvvuri¹, Runa Kuley¹, David Cuthbertson², Peter Grayson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Antoine Sreih⁷, Kenneth J. Warrington¹¹, Tomas Mustelin¹, Paul Monach¹², Peter Merkel¹³ and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²VA Boston Healthcare System, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].